Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...
A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...
For patients with metastatic uveal melanoma, what are the treatment options? Marlana M. Orloff, M.D.: Metastatic uveal melanoma is unique in that when patients recur, close to 90% or more recur in ...
5d
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors?
Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...
The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing ...
Truist analyst Gregory Renza raised the firm’s price target on Ideaya Biosciences (IDYA) to $60 from $59 and keeps a Buy rating on the shares.
MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...
Researchers have identified a new drug combination that is effective against metastatic uveal melanoma cells in preclinical studies. Uveal melanoma is a very aggressive type of melanoma that affects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback